Atomoxetine prevents working memory loss in hyperactive rats, mediating plastic changes in prefrontal cortex pyramidal neurons
-
Add time:07/17/2019 Source:sciencedirect.com
Attention Deficit Hyperactivity Disorder (ADHD) causes impaired visuospatial working memory (VWM), which primarily maps to the prefrontal cortex. However, little is known about the synaptic processes underlying cognitive loss in ADHD, or those ultimately involved in the preventive effect observed through the clinical use of Atomoxetine (ATX). To investigate the plasticity underlying ADHD related cognitive loss, and that potentially involved in the preventive action of Atomoxetine, allocentric VWM was assessed, as well as the dendritic spine number and proportional density on pyramidal neurons in the prefrontal cerebral cortex layer III of neonatal 6-hydroxydopamine-lesioned rats. The effect of acute ATX treatment was also assessed at 28 days of age. 6-OHDA induced lesions produced increased motor activity and a loss of VWM, concomitant with a reduction in thin spine density. ATX administration reversed cognitive loss, in conjunction with a decrease in thin spines and an increase in mushroom spines. A reduction in the proportion of spines involved in learning in hyperactive animals could account for the loss in cognitive function observed. Considering thin spine density was also reduced after ATX administration, we hypothesized that the restoration in cognitive function recorded could be brought about by an increase in memory related mushroom spines.
We also recommend Trading Suppliers and Manufacturers of Atomoxetine hydrochloride (cas 82248-59-7). Pls Click Website Link as below: cas 82248-59-7 suppliers
Prev:Atomoxetine hydrochloride (cas 82248-59-7) for the treatment of attention-deficit/hyperactivity disorder
Next:Atomoxetine, a selective norepinephrine reuptake inhibitor, improves short-term histological outcomes after hypoxic-ischemic brain injury in the neonatal male rat) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Atomoxetine reduces hyperactive/impulsive behaviours in neurokinin-1 receptor ‘knockout’ mice07/24/2019
- Changes in serum miRNA-let-7 level in children with attention deficit hyperactivity disorder treated by repetitive transcranial magnetic stimulation or atomoxetine: An exploratory trial07/23/2019
- Conditioned place preference studies with atomoxetine in an animal model of ADHD: Effects of previous atomoxetine treatment07/22/2019
- Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the α2-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson’s disease07/20/2019
- Atomoxetine hydrochloride (cas 82248-59-7) in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study07/21/2019
- Determination of the enantiomer and positional isomer impurities in Atomoxetine hydrochloride (cas 82248-59-7) with liquid chromatography using polysaccharide chiral stationary phases07/19/2019
- Atomoxetine, a selective norepinephrine reuptake inhibitor, improves short-term histological outcomes after hypoxic-ischemic brain injury in the neonatal male rat07/18/2019
- Atomoxetine hydrochloride (cas 82248-59-7) for the treatment of attention-deficit/hyperactivity disorder07/16/2019
- A quality by design approach to impurity method development for Atomoxetine hydrochloride (cas 82248-59-7) (LY139603)07/15/2019
-
Health and Chemical more >


